IXICO to Present Abstracts at Upcoming Clinical Trials on Alzheimer’s Disease Congress

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience clinical drug development, today announces that it is scheduled to attend and present scientific posters at the 2019 Clinical Trials on Alzheimer’s Disease (CTAD) Congress held from 4th-7th December 2019 in San Diego, California, USA.

CTAD Congress 2019

4th – 7th December 2019, Hilton Bayfront, San Diego, USA

IXICO will present three posters during break-out sessions in the Indigo Foyer on Thursday, 5th December.  Details of the posters are as follows:

“Classifying cognitively healthy subjects from mild cognitive impaired and Alzheimer’s disease patients using Tau-PET: the role of spatial resolution and PET pre-processing”

Given the connection between Alzheimer’s disease and the spatial bio-distribution of misfolded phosphorylated Tau protein, this research investigates how the uptake of Tau-PET scans differs in patients affected with different degrees of cognitive impairment.

Read more